OR WAIT 15 SECS
TxCell signs strategic agreement with MaSTherCell for European manufacturing of its cell therapy products.
TxCell SA, a biotechnology company developing innovative, personalized cell immunotherapies using regulatory T-cells to treat severe chronic inflammatory and autoimmune diseases, announced on Dec. 3, 2015 that it has signed a five-year agreement with MaSTherCell, a contract manufacturing organization (CMO) based in Belgium.
The agreement means MaSTherCell will be the exclusive European manufacturer of all products from TxCell’s ASTrIA platform. TxCell appointed MaSTherCell in July 2015 for the manufacturing of TxCell’s lead product Ovasave, a personalized T cell immunotherapy product, based on the properties of autologous ovalbumin-specific regulatory T lymphocytes, for the ongoing CATS29 study. CATS29 is a Phase IIb trial of Ovasave, conducted in refractory Crohn’s diseases patients.
With the new agreement, the transfer of manufacturing will be extended to Col-Treg, a drug developed to treat Autoimmune Uvetis and TxCell’s second lead product. Col-Treg is expected to enter a clinical trial by the end of 2016 targeting non-infectious uveitis.
Exclusivity will not apply to TxCell (as a potential manufacturer) or to its future licensees. Other contractual terms and conditions were not disclosed.